Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 65% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Supernus Pharmaceuticals Q3 revenue rises 18% on CNS growth

By Reuters News


Overview

  • U.S. CNS drugmaker's Q3 total revenue rose 18% yr/yr on strong growth products

  • Adjusted operating earnings for Q3 increased from prior year, driven by higher revenue

  • Company expects Indivior merger to close Nov. 2, creating larger CNS biopharma


Outlook

  • Company raises 2026 full-year revenue guidance to $875 mln-$900 mln

  • Supernus expects 2026 adjusted operating earnings of $160 mln-$180 mln

  • Company says 2026 guidance will no longer apply after Indivior merger closes Nov. 2, 2026


Result Drivers

  • GROWTH PRODUCTS - Co said revenue growth was driven by higher net sales of Qelbree, GOCOVRI, ZURZUVAE, and ONAPGO

  • ZURZUVAE COLLABORATION - Collaboration revenue from ZURZUVAE more than doubled, with U.S. sales reported by Biogen up 53% yr/yr

  • ONAPGO DEMAND - ONAPGO net sales more than doubled, supported by prescription growth and orphan-drug approval


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Product Sales

$178.60 mln

Q3 Adjusted Revenue from commercial products

$220.30 mln

Q3 Operating Earnings

$21.18 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy"

  • Wall Street's median 12-month price target for Supernus Pharmaceuticals, Inc. is $65.00, about 58.2% above its October 28 closing price of $41.08

  • The stock recently traded at 11 times the next 12-month earnings vs. a P/E of 15 three months ago


Reuters Recommended Reads

  • Oct 29 - Indivior Pharmaceuticals tops Q3 revenue estimates, net income hits record

  • Oct 28 - Biogen Q3 revenue beats on Apellis acquisition, product demand

  • Oct 28 - Biogen tops quarterly estimates on rare-disease drug strength


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.
 

Cryptocurrency-related content is intended solely as news and market commentary. Crypto Derivatives are not available to Retail clients registered with Capital Com (UK) Ltd.